ARCTURUS THERAPEUTICS HOLDINGS INC. Capital Expenditures Incurred but Not yet Paid
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Capital Expenditures Incurred but Not yet Paid of $87.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was -$348.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was -$161.00K, a 125.68% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $470.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $107.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for fiscal 2023 was $68.00K, a 88.13% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for fiscal 2022 was $573.00K, a 981.13% increase from fiscal 2021.
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for fiscal 2021 was $53.00K, a 68.64% decline from fiscal 2020.
- ARCTURUS THERAPEUTICS HOLDINGS INC. capital expenditures incurred but not yet paid for fiscal 2020 was $169.00K, a 29.58% decline from fiscal 2019.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-09-30 | $87.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | -$348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$509.00K derived: sum of 2 quarters · filed 2026-03-03 | -$39.00K derived: sum of 3 quarters · filed 2026-03-03 | $68.00K 10-K · filed 2026-03-03 |
| 2023-09-30 | -$161.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $309.00K derived: sum of 2 quarters · filed 2024-11-07 | $416.00K 10-Q · filed 2024-11-07 | -$1.77M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $577.00K 10-Q · filed 2024-08-05 | -$1.61M derived: sum of 3 quarters · filed 2025-03-06 | -$984.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $107.00K 10-Q · filed 2024-05-08 | -$2.08M derived: sum of 2 quarters · filed 2025-03-06 | -$1.45M derived: sum of 3 quarters · filed 2025-03-06 | |
| 2022-12-31 | -$2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$1.56M derived: sum of 2 quarters · filed 2025-03-06 | $573.00K 10-K · filed 2025-03-06 | |
| 2022-09-30 | $627.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.76M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $2.13M 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$48.00K derived: sum of 2 quarters · filed 2024-03-14 | -$185.00K derived: sum of 3 quarters · filed 2024-03-14 | $53.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$178.00K derived: sum of 2 quarters · filed 2022-11-09 | $60.00K 10-Q · filed 2022-11-09 | -$441.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $101.00K 10-Q · filed 2022-08-09 | -$400.00K derived: sum of 3 quarters · filed 2022-08-09 | $226.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $238.00K 10-Q · filed 2022-05-09 | -$263.00K derived: sum of 2 quarters · filed 2022-05-09 | $363.00K derived: sum of 3 quarters · filed 2022-05-09 | $145.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$501.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $125.00K derived: sum of 2 quarters · filed 2022-03-01 | -$93.00K derived: sum of 3 quarters · filed 2022-03-01 | $169.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $626.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $408.00K derived: sum of 2 quarters · filed 2021-11-09 | $670.00K 10-Q · filed 2021-11-09 | $784.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$218.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $44.00K 10-Q · filed 2021-08-10 | $158.00K derived: sum of 3 quarters · filed 2022-03-01 | $268.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $262.00K 10-Q · filed 2021-05-10 | $376.00K derived: sum of 2 quarters · filed 2022-03-01 | $486.00K derived: sum of 3 quarters · filed 2022-03-01 | $367.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $224.00K derived: sum of 2 quarters · filed 2022-03-01 | $105.00K derived: sum of 3 quarters · filed 2022-03-01 | $240.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$9.00K derived: sum of 2 quarters · filed 2020-11-09 | $126.00K 10-Q · filed 2020-11-09 | -$21.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $16.00K 10-Q · filed 2020-08-10 | -$131.00K derived: sum of 3 quarters · filed 2021-03-01 | -$104.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $135.00K 10-Q · filed 2020-05-08 | -$12.00K derived: sum of 2 quarters · filed 2021-03-01 | $15.00K derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | -$147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$120.00K derived: sum of 2 quarters · filed 2021-03-01 | $30.00K 10-K · filed 2021-03-01 | |
| 2018-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $177.00K 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $150.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |